Melanoma: all 3,073 studies

Page 18 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerCompletedNCT04067960Early Phase 1
• Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for MelanomaCompletedNCT04066725Phase 2
• Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for MelanomaCompletedNCT04062032Phase 2
• CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2
• TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaCompletedNCT04059224Phase 2
• Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer TreatmentsActive, not recruitingNCT04056247
• ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)Active, not recruitingNCT04044859Phase 1
• SBRT as a Vaccination for Metastatic MelanomaWithdrawnNCT04042506Phase 2
• Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI)CompletedNCT04040114Not applicable
• Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated MelanomaCompletedNCT04039672Not applicable
• Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)Status unknownNCT04025424
• Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaStatus unknownNCT04021420Phase 1/2
• Neoadjuvant Atezolizumab in Cutaneous MelanomaActive, not recruitingNCT04020809Phase 1
• The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic MelanomaStatus unknownNCT04017897Phase 2
• Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabActive, not recruitingNCT04013854Phase 2
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT04007744Phase 1
• A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2
• Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain MetastasesStatus unknownNCT04001725Phase 2
• Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.CompletedNCT03993678Phase 1/2
• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant MelanomaStatus unknownNCT03991975Phase 1/2
• Apatinib Plus SHR1210 in Advanced Mucosal MelanomaStatus unknownNCT03986515Phase 2
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
• PDR001 + Panobinostat for Melanoma and NSCLCWithdrawnNCT03982134Phase 1
• A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCompletedNCT03980314Phase 1
• MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) MelanomaCompletedNCT03979651Not applicable
• A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTerminatedNCT03978611Phase 1
• Study of HL-085 in NRAS Mutant Advanced MelanomaCompletedNCT03973151Phase 1/2
• Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant MelanomaWithdrawnNCT03972046Phase 2
• Real World Study of Four PD-1 Agents in ChinaStatus unknownNCT03966456
• PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral MelanomaStatus unknownNCT03955354Phase 2
• Dietary Intervention in Patients with a History of MelanomaTerminatedNCT03950635Phase 1
• Cryotherapy With in Situ Immunotherapy in Melanoma MetastasisCompletedNCT03949153Phase 1/2
• Quality of Life and Physical Fitness After Immune Checkpoint InhibitorsCompletedNCT03946007
• BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma PatientsCompletedNCT03944356
• Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaStatus unknownNCT03941795Phase 2
• MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)SuspendedNCT03932253Phase 1
• The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic MelanomaWithdrawnNCT03928275Phase 2/3
• Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) MutationStatus unknownNCT03925350Phase 2
• Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal MelanomaCompletedNCT03922880Phase 1
• Nab-PCE vs PC for MM After Failure of Anti-PD-1Status unknownNCT03917069Phase 2
• Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsActive, not recruitingNCT03915678Phase 2
• Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03913923Phase 2
• Tinostamustine and Nivolumab in Advanced MelanomaStatus unknownNCT03903458Phase 1
• The Use of Magtrace®/Sentimag® in Sentinel Node Biopsy for Malignant Melanoma. The Magmen Study.CompletedNCT03898687Not applicable
• An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)Active, not recruitingNCT03897881Phase 2
• MB-CART20.1 MelanomaTerminatedNCT03893019Early Phase 1
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingNCT03891953Phase 1
• Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort StudyCompletedNCT03879395
• Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant MelanomaTerminatedNCT03878719Phase 1
• A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaCompletedNCT03875079Phase 1
• A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedNCT03872947Phase 1
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV MelanomaTerminatedNCT03865212Phase 1
• A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
• A Study To See Why Patients Agree To or Decline To Have Treatment After SurgeryCompletedNCT03843593
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1
• 3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With MelanomaTerminatedNCT03825913Not applicable
• Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PIIStatus unknownNCT03818893Phase 2
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck CancerTerminatedNCT03809624Phase 1
• CAcTUS - Circulating Tumour DNA Guided SwitchActive, not recruitingNCT03808441Phase 2
• Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community SettingWithdrawnNCT03804255
• Preclinical Validation of New Anti-melanoma CompoundsCompletedNCT03798977
• Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012CompletedNCT03784625Early Phase 1
• Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and MelanomaCompletedNCT03783325Not applicable
• This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)Status unknownNCT03780608Phase 2
• MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnNCT03773744Phase 1
• Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)Active, not recruitingNCT03772899Phase 1
• A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedCompletedNCT03771859
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingNCT03767348Phase 2
• MGD019 DART® Protein in Unresectable/Metastatic CancerCompletedNCT03761017Phase 1
• Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.WithdrawnNCT03758729Phase 2
• Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C MelanomaActive, not recruitingNCT03757689Phase 2
• Assessing Patient Anxiety During Mohs Micrographic SurgeryCompletedNCT03756792Not applicable
• Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaStatus unknownNCT03754179Phase 1/2
• Intralesional Sclerosant for in Transit and Cutaneous Melanoma MetastasesWithdrawnNCT03754140Phase 2
• A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedNCT03752398Phase 1
• Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)Status unknownNCT03747744Phase 1
• SunSmart Intervention in SchoolsCompletedNCT03745872Not applicable
• 18FDG-PET in Patients With Melanoma or NSCLC Treated With ImmunotherapyCompletedNCT03741231
• A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the USCompletedNCT03732560
• Spontaneous Regression in Metastatic Melanoma and Renal Cell CarcinomaActive, not recruitingNCT03728842
• Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2
• CBL0137 in Treating Patients With Advanced Extremity Melanoma or SarcomaTerminatedNCT03727789Phase 1
• Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated MelanomaTerminatedNCT03727087
• Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for MelanomaCompletedNCT03725449Not applicable
• Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) OximetryTerminatedNCT03716193Not applicable
• Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)Status unknownNCT03715985Phase 1/2
• MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for MelanomaTerminatedNCT03699995Not applicable
• Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain MetastasesTerminatedNCT03698162Not applicable
• A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced MelanomaCompletedNCT03696069
• A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk GroupsCompletedNCT03693378
• Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsTerminatedNCT03684785Phase 1/2
• Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in MelanomaActive, not recruitingNCT03683550Not applicable
• Safety of ADU-1604 in Adults With Metastatic MelanomaTerminatedNCT03674502Phase 1
• Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPiesTerminatedNCT03673332Phase 4
• Advanced Melanoma in Russian ExperienceCompletedNCT03663647
• High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower LimbsCompletedNCT03653819Not applicable
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• Treatment of Malignant Melanoma With GPA-TriMAR-T Cell TherapyStatus unknownNCT03649529Early Phase 1
• Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic MelanomaActive, not recruitingNCT03646617Phase 2
• Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsTerminatedNCT03645928Phase 2

← Melanoma overview